Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine

R. Casolino; C. Braconi; G. Malleo; S. Paiella; C. Bassi; M. Milella; S. B. Dreyer; F. E.M. Froeling; D. K. Chang; A. V. Biankin; T. Golan

doi:10.1016/j.annonc.2020.11.013

Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine

R. Casolino, C. Braconi, G. Malleo, S. Paiella, C. Bassi, M. Milella, S. B. Dreyer, F. E.M. Froeling, D. K. Chang, A. V. Biankin^*, T. Golan

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

44 Scopus citations

Abstract

This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of ‘all-comer’ treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.

Original language	English
Pages (from-to)	183-196
Number of pages	14
Journal	Annals of Oncology
Volume	32
Issue number	2
DOIs	https://doi.org/10.1016/j.annonc.2020.11.013
State	Published - Feb 2021
Externally published	Yes

Keywords

Pancreatic cancer
neoadjuvant
precision medicine
predictive biomarkers
preoperative
prognostic biomarkers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2020.11.013

Cite this

@article{5732d4b2345249d7a9f2b7be76966c7f,

title = "Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine",

abstract = "This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of {\textquoteleft}all-comer{\textquoteright} treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.",

keywords = "Pancreatic cancer, neoadjuvant, precision medicine, predictive biomarkers, preoperative, prognostic biomarkers",

author = "R. Casolino and C. Braconi and G. Malleo and S. Paiella and C. Bassi and M. Milella and Dreyer, {S. B.} and Froeling, {F. E.M.} and Chang, {D. K.} and Biankin, {A. V.} and T. Golan",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2021",

month = feb,

doi = "10.1016/j.annonc.2020.11.013",

language = "אנגלית",

volume = "32",

pages = "183--196",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine

AU - Casolino, R.

AU - Braconi, C.

AU - Malleo, G.

AU - Paiella, S.

AU - Bassi, C.

AU - Milella, M.

AU - Dreyer, S. B.

AU - Froeling, F. E.M.

AU - Chang, D. K.

AU - Biankin, A. V.

AU - Golan, T.

PY - 2021/2

Y1 - 2021/2

N2 - This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of ‘all-comer’ treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.

AB - This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of ‘all-comer’ treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.

KW - Pancreatic cancer

KW - neoadjuvant

KW - precision medicine

KW - predictive biomarkers

KW - preoperative

KW - prognostic biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85098623479&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.11.013

DO - 10.1016/j.annonc.2020.11.013

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 33248227

AN - SCOPUS:85098623479

SN - 0923-7534

VL - 32

SP - 183

EP - 196

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -

Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this